Protection against persistence of hepatitis C

Shruti Hemendra Mehta, Andrea Cox, Donald R. Hoover, Xiao Hong Wang, Qing Mao, Stuart Campbell Ray, Steffanie A. Strathdee, David Vlahov, David L Thomas

Research output: Contribution to journalArticle

Abstract

Background: Neither previous hepatitis C virus (HCV) infection nor vaccination with HCV-derived antigens protects against reinfection. However, HCV infection and vaccination in chimpanzees has been shown to reduce the magnitude and duration of viraemia with re-challenge. We aimed to establish whether similar immunity could be achieved in man. Methods: From a study of injecting drug users, we identified 164 people who had no evidence of previous HCV infection and 98 individuals who had been previously, but were not currently, infected with HCV. We compared the incidence and persistence of HCV viraemia in these two groups over four consecutive 6-month periods. Findings: Of participants without previous infection, the incidence of HCV infection was 21% (35/164). By contrast, people previously infected were half as likely to develop new viraemia (12% [12/98]), even after accounting for risk behaviour (hazard ratio, 0·45; 95% CI 0·23-0·88). Furthermore, in HIV-1-negative people, those previously infected were 12 times less likely than people infected for the first time to develop persistent infection (odds ratio 0·05, 95% CI 0·01-0·30), and median peak HCV RNA concentration was two logs lower. HCV persisted in six of six HIV-1-positive people, even in one man who had previously cleared HCV infection when he was HIV-1 negative. Interpretation: There is an alarming frequency of HCV infection and persistence among injecting drug users. Our data suggest that immunity against viral persistence can be acquired, and that vaccines should be tested to reduce the burden of HCV-related liver disease.

Original languageEnglish (US)
Pages (from-to)1478-1483
Number of pages6
JournalThe Lancet
Volume359
Issue number9316
DOIs
StatePublished - Apr 27 2002

Fingerprint

Hepatitis C
Hepacivirus
Virus Diseases
Viremia
HIV-1
Drug Users
Immunity
Vaccination
Pan troglodytes
Incidence
Risk-Taking
Infection
Liver Diseases
Vaccines
Odds Ratio
RNA
Antigens

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Protection against persistence of hepatitis C. / Mehta, Shruti Hemendra; Cox, Andrea; Hoover, Donald R.; Wang, Xiao Hong; Mao, Qing; Ray, Stuart Campbell; Strathdee, Steffanie A.; Vlahov, David; Thomas, David L.

In: The Lancet, Vol. 359, No. 9316, 27.04.2002, p. 1478-1483.

Research output: Contribution to journalArticle

Mehta, SH, Cox, A, Hoover, DR, Wang, XH, Mao, Q, Ray, SC, Strathdee, SA, Vlahov, D & Thomas, DL 2002, 'Protection against persistence of hepatitis C', The Lancet, vol. 359, no. 9316, pp. 1478-1483. https://doi.org/10.1016/S0140-6736(02)08435-0
Mehta, Shruti Hemendra ; Cox, Andrea ; Hoover, Donald R. ; Wang, Xiao Hong ; Mao, Qing ; Ray, Stuart Campbell ; Strathdee, Steffanie A. ; Vlahov, David ; Thomas, David L. / Protection against persistence of hepatitis C. In: The Lancet. 2002 ; Vol. 359, No. 9316. pp. 1478-1483.
@article{2f720bf53db24007a25761ccc8c86b93,
title = "Protection against persistence of hepatitis C",
abstract = "Background: Neither previous hepatitis C virus (HCV) infection nor vaccination with HCV-derived antigens protects against reinfection. However, HCV infection and vaccination in chimpanzees has been shown to reduce the magnitude and duration of viraemia with re-challenge. We aimed to establish whether similar immunity could be achieved in man. Methods: From a study of injecting drug users, we identified 164 people who had no evidence of previous HCV infection and 98 individuals who had been previously, but were not currently, infected with HCV. We compared the incidence and persistence of HCV viraemia in these two groups over four consecutive 6-month periods. Findings: Of participants without previous infection, the incidence of HCV infection was 21{\%} (35/164). By contrast, people previously infected were half as likely to develop new viraemia (12{\%} [12/98]), even after accounting for risk behaviour (hazard ratio, 0·45; 95{\%} CI 0·23-0·88). Furthermore, in HIV-1-negative people, those previously infected were 12 times less likely than people infected for the first time to develop persistent infection (odds ratio 0·05, 95{\%} CI 0·01-0·30), and median peak HCV RNA concentration was two logs lower. HCV persisted in six of six HIV-1-positive people, even in one man who had previously cleared HCV infection when he was HIV-1 negative. Interpretation: There is an alarming frequency of HCV infection and persistence among injecting drug users. Our data suggest that immunity against viral persistence can be acquired, and that vaccines should be tested to reduce the burden of HCV-related liver disease.",
author = "Mehta, {Shruti Hemendra} and Andrea Cox and Hoover, {Donald R.} and Wang, {Xiao Hong} and Qing Mao and Ray, {Stuart Campbell} and Strathdee, {Steffanie A.} and David Vlahov and Thomas, {David L}",
year = "2002",
month = "4",
day = "27",
doi = "10.1016/S0140-6736(02)08435-0",
language = "English (US)",
volume = "359",
pages = "1478--1483",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9316",

}

TY - JOUR

T1 - Protection against persistence of hepatitis C

AU - Mehta, Shruti Hemendra

AU - Cox, Andrea

AU - Hoover, Donald R.

AU - Wang, Xiao Hong

AU - Mao, Qing

AU - Ray, Stuart Campbell

AU - Strathdee, Steffanie A.

AU - Vlahov, David

AU - Thomas, David L

PY - 2002/4/27

Y1 - 2002/4/27

N2 - Background: Neither previous hepatitis C virus (HCV) infection nor vaccination with HCV-derived antigens protects against reinfection. However, HCV infection and vaccination in chimpanzees has been shown to reduce the magnitude and duration of viraemia with re-challenge. We aimed to establish whether similar immunity could be achieved in man. Methods: From a study of injecting drug users, we identified 164 people who had no evidence of previous HCV infection and 98 individuals who had been previously, but were not currently, infected with HCV. We compared the incidence and persistence of HCV viraemia in these two groups over four consecutive 6-month periods. Findings: Of participants without previous infection, the incidence of HCV infection was 21% (35/164). By contrast, people previously infected were half as likely to develop new viraemia (12% [12/98]), even after accounting for risk behaviour (hazard ratio, 0·45; 95% CI 0·23-0·88). Furthermore, in HIV-1-negative people, those previously infected were 12 times less likely than people infected for the first time to develop persistent infection (odds ratio 0·05, 95% CI 0·01-0·30), and median peak HCV RNA concentration was two logs lower. HCV persisted in six of six HIV-1-positive people, even in one man who had previously cleared HCV infection when he was HIV-1 negative. Interpretation: There is an alarming frequency of HCV infection and persistence among injecting drug users. Our data suggest that immunity against viral persistence can be acquired, and that vaccines should be tested to reduce the burden of HCV-related liver disease.

AB - Background: Neither previous hepatitis C virus (HCV) infection nor vaccination with HCV-derived antigens protects against reinfection. However, HCV infection and vaccination in chimpanzees has been shown to reduce the magnitude and duration of viraemia with re-challenge. We aimed to establish whether similar immunity could be achieved in man. Methods: From a study of injecting drug users, we identified 164 people who had no evidence of previous HCV infection and 98 individuals who had been previously, but were not currently, infected with HCV. We compared the incidence and persistence of HCV viraemia in these two groups over four consecutive 6-month periods. Findings: Of participants without previous infection, the incidence of HCV infection was 21% (35/164). By contrast, people previously infected were half as likely to develop new viraemia (12% [12/98]), even after accounting for risk behaviour (hazard ratio, 0·45; 95% CI 0·23-0·88). Furthermore, in HIV-1-negative people, those previously infected were 12 times less likely than people infected for the first time to develop persistent infection (odds ratio 0·05, 95% CI 0·01-0·30), and median peak HCV RNA concentration was two logs lower. HCV persisted in six of six HIV-1-positive people, even in one man who had previously cleared HCV infection when he was HIV-1 negative. Interpretation: There is an alarming frequency of HCV infection and persistence among injecting drug users. Our data suggest that immunity against viral persistence can be acquired, and that vaccines should be tested to reduce the burden of HCV-related liver disease.

UR - http://www.scopus.com/inward/record.url?scp=0037181727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037181727&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(02)08435-0

DO - 10.1016/S0140-6736(02)08435-0

M3 - Article

C2 - 11988247

AN - SCOPUS:0037181727

VL - 359

SP - 1478

EP - 1483

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9316

ER -